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Traditionalknowledgeisanimportantsourceofobtainingnewphytotherapeuticagents.Ethnobotanicalsurveyofmedicinalplants
was conducted in Nossa Senhora Aparecida do Chumbo District (NSACD), located in Pocon´ e, Mato Grosso, Brazil using semi-
structured questionnaires and interviews. 376 species of medicinal plants belonging to 285 genera and 102 families were cited.
Fabaceae (10.2%), Asteraceae (7.82%) and Lamaceae (4.89%) families are of greater importance. Species with the greater relative
importancewereHimatanthusobovatus(1.87),Hibiscussabdariﬀa(1.87),Solidagomicroglossa(1.80),Strychnospseudoquina(1.73)
and Dorstenia brasiliensis, Scoparia dulcis L., and Luehea divaricata (1.50). The informant consensus factor (ICF) ranged from 0.13
to 0.78 encompassing 18 disease categories,of which 15 had ICF greater than 0.50, with a predominance of disease categories
related to injuries, poisoning and certain other consequences of external causes (ICF = 0.78) having 65 species cited while 20
species were cited for mental and behavioral disorders (ICF = 0.77). The results show that knowledge about medicinal plants is
evenly distributed among the population of NSACD. This population possesses medicinal plants for most disease categories, with
the highest concordance for prenatal, mental/behavioral and respiratory problems.
1.Introduction
Despite the fact that modern medicine, on the basis of the
complex pharmaceutical industry, is well developed in most
part of the world, the World Health Organization (WHO)
through it Traditional Medicine Program recommends its
Member States to formulate and develop policies for the
use of complementary and alternative medicine (CAM)
in their national health care programmes [1]. Among the
components of CAM, phytotherapy practiced by the greater
percentage of the world population through the use of
plants or their derivatives, occupies a signiﬁcant and unique
position [2].
In this sense, documentation of the indigenous knowl-
edge through ethnobotanical studies is important in the
conservation and utilization of biological resources [3].
Brazil is a country with ﬂoral megadiversity, possessing
six ecological domains, namely, Amazonian forest, Caatinga,
Pampas,Cerrado,AtlanticForest,andthePantanal[4].Mato
Grosso region is noteworthy in this regard, as it occupies a
prominent position both in the national and international
settings, for it presents three major Brazilian ecosystems (the
Pantanal, Cerrado, and Amazonian rainforest). Besides this,
it also hosts diverse traditional communities in its territo-
ries, namely, the Indians descents (Amerindians), African
descents, and the white Europeans. However, due to the mass2 Evidence-Based Complementary and Alternative Medicine
migration from the rural areas and technological develop-
ment, coupled with globalization of knowledge by the domi-
nant nations, cultural tradition concerning the use of medic-
inal plants is in the major phase of declining [5].
The Pantanal is distinguishably the largest wetland
ecosystem of the world, according to the classiﬁcation by
UNESCO World Heritage Center (Biosphere Reserve) [4].
The Pantanal vegetation is a mosaic consisting of species
of the Amazonian rainforest, Cerrado, Atlantic forest, and
Bolivian Chaco, adapted to special conditions, where there is
alternations of both high humidity and pronounced dryness
during the time of the year [4]. The presence in the Pantanal
of the traditional populations that use medicinal plants for
basic health care makes this region an important ﬁeld for the
ethnobotanical and ethnopharmacological studies [6, 7].
Because of the fact that the Pantanal communities are
relatively isolated, they have developed private lives that
involved much reliance on profound knowledge of the bio-
logical cycles, utilization of natural resources, and traditional
technology heritage [8].
As a result of the aforementioned, this study aimed to
systematically and quantitatively evaluate the information
gathered from these Pantanal communities, highlight the
relevanceoftheethnobotanicalﬁndings,andciteanddiscuss
relevant literatures related to medicinal plants with greater
relative importance (RI) and high informant consensus
factor (ICF) values obtained in the study.
2.MaterialsandMethods
2.1. Study Area. For the choice of study area, literature
search was conducted to identify the Pantanal region in
Mato Grosso, consisting of traditional communities where
such studies have not yet been conducted and/or there were
no ethnobotanical survey publications. The study design
was cross-sectional and was conducted between the period
of November, 2009 and February, 2010. The study setting
chosen was NSACD located in the Pocon´ e municipality,
Mato Grosso State, Central West of Brazil (Figure 1)w i t h
coordinates of 16◦ 02  90   S and 056◦ 43  49   W. Pocon´ ei s
located within the region of Cuiab´ a River valley, with an alti-
tude of 142m, occupies a territorial area of 17,260.86km2,
and of tropical climate. The mean annual temperature is
24◦C (4–42◦C) and the mean annual rainfall is 1,500mm
with rainy season occurring between December and Febru-
ary. The municipality is composed of 2 Districts (NSAC
and Cangas), 5 villages, 11 settlements, 14 streets, and 72
communities (countryside) [9]. The population of NSACD
is estimated to be 3,652 inhabitants, representing 11.5% of
Pocon´ e municipality [10]. The principal economic activities
are mainly livestock farming, mining, and agriculture with
great tourism potentials, because Pocon´ e municipality is the
gateway to the Pantanal region [9].
2.2. Consent and Ethical Approval. Authorization and ethical
clearance were sought from the relevant government (Health
authority of Pocon´ e and the National Council of Genetic
Heritage of the Ministry of Environment (CGEN/MMA),
Resolution 247 published in the Federal Oﬃcial Gazette, in
October, 2009, on access to the traditional knowledge for
scientiﬁcresearchandFederalUniversityofMatoGrossoand
J´ ulio Muller Hospital Research Ethical Committees, Protocol
561/CEP-HUJM/08 authorities. Previsits were made to each
community of NSACD to present the research project as well
as to seek the consent of each potential informant.
2.3. Data Collection and Analysis. In this present study, sam-
plingwasdoneusingprobabilisticsimplerandomizationand
stratiﬁed sampling techniques [10, 11].
The population studied consists of inhabitants of 13
communities of NSACD, Mato Grosso State, considering an
informant per family. The criteria for each informant chosen
were age of 40 and above, residing in NSACD for more than
5years(becausethereislargemigrationintotheareabecause
of the presence of ethanol producing factory).
These criteria are in line with the study objective coupled
with the information gathered from the local authority [12].
In order to determine the estimated sample size (n),
in this case, the number of families to be sampled per












This study considered the population size of 1,179
families (N = 1, 179), conﬁdence coeﬃcient of 95% (z/2 =
1.96), sampling error of 0.05 (d = 0.05), a proportion of 0.5
(P = 0.5). It should be noted that the P = 0.5 was assigned
duetononexistenceofpreviousinformationaboutthisvalue
as is usual in practice, to obtain conservative sample size
which is representative at the same time.
In determining the sample size for the microarea, 5%
error and 10% loss in sample were considered. To determine
the sample size in each microarea, the sample size (290) was
multiplied by the sampling fraction of each microarea and
dividing the total number of families of the same microarea
with the total number of families of all the microareas
(1,179), thereby arriving at the sample sizes for each area as
shown in Table 1.
The interviews were conducted with the help of 12
trained applicators, under the supervision of the respec-
tive investigator. Data collected included sociodemographic
details, vernacular names of the plant species with their
medicinal uses, methods of drug preparation, and other
relevant information. The ethnobotanical data were orga-
nized using the Microsoft Oﬃce Access 2003 program and
statistically analyzed using SPSS, version 15 for Windows
(SPSS Inc., Chicago, Illinois, USA).
2.4. Plant Collection, Identiﬁcation, and Herborization. The
collection of plant materials were done in collaboration
with the local specialists, soon after the interviews. Both
indigenous and scientiﬁc plant names were compiled. The
plant materials collected during the study period were
herborized, mounted as herbarium voucher specimens, and
deposited for taxonomic identiﬁcation and inclusion in theEvidence-Based Complementary and Alternative Medicine 3
Figure 1: Location of the study area. Pocon´ e, Mato Grosso, in Midwest of Brazil.
Table 1: Distribution of the 13 communities of Nossa Senhora Aparecida do Chumbo District.








1 Chumbo 946 216 0.1832 52
2 Canto do Agostinho, Santa Helena, Os Cagados, V´ arzea bonita 179 52 0.0441 15
3 Furnas II, Salobra, Z´ e Alves 165 59 0.0500 15
4 Campina II, Furnas I, Mundo Novo, Rodeio 279 81 0.0687 20
5 Campina de Pedra, Imb´ e 188 67 0.0568 16
6 Barreirinho, Coetinho, Figueira 253 95 0.0806 23
7 Bahia de Campo 257 74 0.0628 18
8 Agrovila, S˜ ao Benedito 184 66 0.0560 16
9 Agroana 372 178 0. 1510 44
10 Bandeira, Minadouro 248 82 0.0696 20
11 Carret˜ ao, Deus Ajuda, Sangradouro, Pesqueiro, Varzearia 216 77 0.0653 19
12 Chafariz, Ramos, Sete Porcos, Urubamba 208 67 0.0568 16
13 C´ eu Azul, Cap˜ ao Verde, Morro Cortado, Passagem de Carro, Varal 157 65 0.0551 16
Total 3,652 1,179 1.0000 290
ID = identiﬁcation of the microarea.
collection of Federal University of Mato Grosso and CGMS
Herbarium of Federal University of Mato Grosso do Sul,
Brazil.
Plant species were identiﬁed according to standard
taxonomic methods, based on ﬂoral morphological char-
acters, analytical keys, and using, where possible, samples
for comparison, as well as consultations with experts and
literature [6, 7, 14–19]. The plant species obtained were
grouped into families according to the classiﬁcation system
of Cronquist [20], with the exception of the Pteridophyta
and Gymnospermae. For corrections of scientiﬁc names and
families,theoﬃcialwebsiteoftheMissouriBotanicalGarden
was consulted [21].
2.5. Quantitative Ethnobotany. T h er e l a t i v ei m p o r t a n c e( R I )
of each plant species cited by the informants was calculated
according to a previously proposed method [22]. In order to
calculate RI, the maximum obtainable by a species is two was
calculated using (2) according to Oliveira et al. [23]
RI = NCS + NP, (2)
where RI: relative importance; NCS: number of body sys-
tems. It is given by the number of body systems, treated by a
species (NSCS) over the total number of body system treated
bythemostversatilespecies(NSCSV):NCS =NSCS/NSCSV;
N P :n u m b e ro fp r o p e r t i e sa t t r i b u t e dt oas p e c i ﬁ cs p e c i e s4 Evidence-Based Complementary and Alternative Medicine
(NPS) over the total number of properties attributed to the
most versatile species (NPSV): NP = NPS/NPSV.
We sought to identify the therapeutic indications which
were more important in the interviews to determine the
informant consensus factor (ICF), which indicates the
homogenity of the information [23].
The ICF will be low (close to 0), if the plants are chosen
randomly, or if the informants do not exchange information
about their uses. The value will be high (close to 1), if there is
a well deﬁned criterion of selection in the community and/or
if the information is exchanged among the informants [23].
ICF was calculated using the number of use citations in
each category of plant disease (nur), minus the number of
species used (nt) divided by the number of use citations in





The citations for therapeutic purposes were classiﬁed
using the 20 categories of the International Classiﬁcation
of Diseases and Related Health Problems, 10th edition-
CID [24]: injuries, certain infectious, and parasitic diseases
(I); neoplasms-tumors (II), diseases of blood and blood-
forming organs and certain disorders involving the immune
mechanism (III), endocrine, nutritional and metabolic dis-
eases (IV) mental and behavioral disorders (V), nervous
system (VI), diseases of eye and adnexa (VII), diseases of
theearandmastoidprocess(VIII),diseasesofthecirculatory
system (IX), respiratory diseases (X), digestive diseases (XI),
diseases of the skin and subcutaneous tissue (XII), diseases
of the musculoskeletal system and connective tissue (XIII),
genitourinary diseases (XIV), pregnancy, childbirth and
(XV), certain conditions originating during the perinatal
period (XVI), symptoms, signs and abnormal clinical and
laboratory ﬁndings, not elsewhere classiﬁed (XVIII) and
injury, poisoning and certain other consequences of external
causes (XIX).
We selected for further discussion species that presented
RI ≥ 1.5, and are in a category with high ICF. We conducted
literature review using among others, the databases of Web
of Science, MEDLINE, SciELO and including nonindexed
works. We also searched national data bases for dissertations
and theses.
3. Results
A total of 262 informants were interviewed, representing
7.17% of the population of NSACD, 22.22% of the popula-
tion aged ≥40 years and residing in the District for over ﬁve
years. Of the respondents, 69% were female and 31% male,
aged 40–94 years (median 55). 68% were born in the city of
Pocon´ e, and 62% have been residents for over 20 years in the
District (Table 2).
Of the 262 respondents, 259 (99.0%) reported the use
of medicinal plants in self health care, with a minimum of
1 plant and a maximum of 250 plants among the female
respondents and a minimum of 2 plants and a maximum of
54 among the male respondents. A total of 3,289 citations
were recorded corresponding to 376 diﬀerent plant species
which belong to 285 genera and 102 families. Fabaceae
(10.2%),Asteraceae(7.82%),andLamaceae(4.89%)families
were the most representative in this study (Table 3).
3.1. Relative Importance (RI). T h eR Io ft h es p e c i e sc i t e db y
262 respondents from NSACD ranged from 0.17 to 1.87. A
total of 261 species had RI ≤ 0.5; 80 species, RI from 0.51
to 1.0; 30 species, RI from 1.1 to 1.5, and 4 species with RI
from1.51to2.0,amongthelatter,threespecieswerenativeto
Brazil.ThespecieswithRI ≥1.5,wereHimatanthusobovatus
(M¨ ull. Arg.) Woodson (1.87), Hibiscus sabdariﬀa L. (1.87),
Solidago microglossa DC. (1.80), Strychnos pseudoquina A.
St.-Hil. (1.73), Dorstenia brasiliensis Lam., Scoparia dulcis L.,
and Luehea divaricata Mart. (1.50 each), as shown in Table 4.
3.2. Informant Consensus Factor (ICF). In the disease cat-
egories according to CID, 10th ed., we observed that ICF
valuesrangedfrom0.43to0.77, withtheexceptionofdisease
categoryincludedinCIDVI(diseasesofthenervoussystem),
which was 0.13. The ICF for CID VI ranged between 0.13
and 0.78 (mean = 0.62, SD = 0.16, 95% CI: 0.53–0.70).
The highest consensus value obtained was for the category
related to injuries, poisoning, and some other consequences
of external causes (ICF = 0.78), with 65 species and 286
citations.Threespeciesweremorecommon,namely,S.dulcis
and S. microglossa (“Brazilian arnica”),with 49 citations each
and L. pacari (manga-brava) with 42 citations. The main
ailments addressed in this category were inﬂammation, pain,
and gastric disorders.
Out of 20 disease categories, there were citations for 18
therapeutic indications, as shown in Table 5.
4. Discussion
In the present study, almost all the respondents (99%)
claimed to know and use medicinal plants. Surveys con-
ducted in other countries had reported values ranging from
42% to 98% depending on the region and country of the
study [25–27]. Due to the low level of knowledge of tradi-
tional medicine in national capitals, ethnobotanical surveys
in many developing countries including Brazil, primarily
prefer to evaluate small communities or rural hometowns,
whose population having knowledge and practical experi-
ence with traditional medicine are proportionately higher
(between 80 and 100%) [28–30].
The high percentage of folk knowledge of medicinal
plants identiﬁed in Brazil may be due to factors such as
lower inﬂuence of the contemporary urban lifestyle and
the strength of cultural traditions in the rural communities
[31]. In fact, with the process of industrialization and
migrationtothecities,asigniﬁcantpartoftraditionalculture
is maintained more in the communities farther from the
metropolis via oral transmission of the knowledge of CAM
and family traditions. Transmission and conservation of
CAM knowledge is more pronounced in Brazil due to high
degree of biodiversity.
One of the most important aspects of this research is
the documentation of high number of taxa (285 genera andEvidence-Based Complementary and Alternative Medicine 5
Table 2: Distribution of the 13 communities of Nossa Senhora Aparecida do Chumbo District, Pocon´ e, Mato Grosso, Brazil.







1 Chumbo 946 216 0.1832 52 50 827
2 Canto do Agostinho, Santa Helena, Os
Cagados, V´ arzea bonita 179 52 0.0441 15 10 131
3 Furnas II, Salobra, Z´ e Alves 165 59 0.050 15 10 99
4 Campina II, Furnas I, Mundo Novo,
Rodeio 279 81 0.0687 20 11 179
5 Campina de Pedra, Imb´ e 188 67 0.0568 16 12 173
6 Barreirinho, Coetinho, Figueira 253 95 0.0806 23 23 213
7 Bahia de Campo 257 74 0.0628 18 13 461
8 Agrovila, S˜ ao Benedito 184 66 0.056 16 16 141
9 Agroana 372 178 0.151 44 38 349
10 Bandeira, Minadouro 248 82 0.0696 20 22 171
11 Carret˜ ao, Deus Ajuda, Sangradouro,
Pesqueiro, Varzearia 216 77 0.0653 19 23 180
12 Chafariz, Ramos, Sete Porcos, Urubamba 208 67 0.0568 16 16 200
13 C´ eu Azul, Cap˜ ao Verde, Morro Cortado,
Passagem de Carro, Varal 157 65 0.0551 16 18 165
N 3,652 1,179 1.000 290 262 3,289
ID: Identiﬁcation of the microarea; N: Sample size; aInformants with age ≥ 40 years and period of residing ≥ 5y e a r s .
102 families) and species (376) mentioned by the informants
as medicinal. These ﬁndings conﬁrmed the existence of
the great diversity of plants used for therapeutic purpose
and preserved traditional culture, as stated by Simbo [32].
It is worth mentioning here the presence of 8 (eight)
local medicinal plant expert informants/healers among the
262 respondents in this study. These local expert infor-
mants/healers account for a signiﬁcant number of citations
(43to250) in thisstudy. In Brazil,asinothercountries, rural
communitieshavedevelopedknowledgeaboutthemedicinal
and therapeutic properties of natural resources and have
contributed to the maintenance and transmission of the
ethnopharmacological knowledge within the communities.
The most representative plant families are Fabaceae
(10.2%), Asteraceae (7.82%), and Lamiaceae (4.89%). These
results are in accordance with other ethnobotanical surveys
conducted in the tropical regions [33, 34] including Brazil
[7, 35]. Furthermore, the results from our study are also
in conformity with the ﬁndings of the most comprehensive
ethnobotanical survey conducted by V. J. Pott and A. Pott in
the Brazilian Pantanal region [19].
Featuring greater potential for bioprospecting are 231
(61.6%) species indicated for the treatment of at least two
diseases, and RI between 0.17 and 1.87 (mean = 0.46, SD
= 0.357, 95% CI: 0.4250–0.4973). The seven species with
the highest RI were H. obovatus (M¨ ull. Arg.) Woodson (13
therapeutic indications and RI = 1.87, H. sabdariﬀa L. (12
therapeutic indications and RI = 1.87); S. microglossa DC.
(9 therapeutic indications and RI = 1.80) S. pseudoquina A.
St. - Hil. (14 therapeutic indications and RI = 1.73) and
D. brasiliensis Lam., S. dulcis L., and L. divaricata Mart.
(12, 10, and 12 therapeutic indications respectively with RI
= 1.50) (Table 4). For the sake of brevity, we will focus
most of our discussion on these seven most cited medicinal
plants highlighting the most important available literature
on them and including L. pacari. It should be noted that
although 146 (39%) species presented RI below 0.17, with
just a single indication, they cannot be considered as of
lower pharmacological potential or importance, because as
Albuquerque et al. [36] have noted elsewhere, these may
be species of recent introduction in the culture of the
community under study but might have been validated by
the customary use in other social groups.
A total of 105 diﬀerent folkways, including 18 disease
categories, according to Brasil [24], were codiﬁed as shown
in Table 5. The highest frequencies in decreasing magnitude
were indications for the treatment of pain and inﬂammation
(10.8%), kidney disease (7.6%), and wound healing (6.8%).
In part, these data can be explained by the characteristics of
the informants (elderly, rural activity, low level of education,
and poor sanitation at home) with higher frequency of
chronic, inﬂammatory, and infectious diseases. In addition,
the search for natural treatments for infected wounds is
very common in populations of agrarian labor or menial
worker as stated by Akerreta et al. [37]. As ICF values were
generallycloseto1.0,itmaybepresumedthatthereiscertain
homogeneity in knowledge of medicinal plants among the
population of NSACD.
4.1. Literature Survey and Discussions on the Selected Species
with Higher Relative Importance. Himatanthus obovatus,v a r .
obovatus had the highest relative importance, being cited
for 13 diﬀerent ailments that fall into 11 categories of CID,
10th ed. with a total of 29 citations. The most commonly
mentioned of these indications for this plant were its6 Evidence-Based Complementary and Alternative Medicine
Table 3: Relation of the relative importance of the plant species mentioned by informants of Nossa Senhora Aparecida do Chumbo District,





listed NCS NP RI
1. ACANTHACEAE




Infusion (I) 36 2 3 0.40
2. ADOXACEAE
2.1. Sambucus australis Cham. & Schltdl. Sabugueiro Fever and measles Infusion (I, E) 24 2 2 0.33
3. ALISMATACEAE






43 4 4 0.67
4. AMARYLLIDACEAE
4.1. Allium cepa L. Cebola wound healing Infusion (I) 1 1 1 0.17
4.2. Allium ﬁstulosum L. Cebolinha Flu Infusion (I) 1 1 1 0.17
4.3. Allium sativum L. Alho hypertension Infusion (I) 7 1 1 0.17
5. AMARANTHACEAE









Infusion (I, E) 41 6 9 1.20
5.2. Alternanthera dentata(Moench) Stuchlik ex R.E. Fr. Ampicilina wound healing
and kidneys Infusion (I, E) 7 2 2 0.33
5.3. Alternanthera ﬁcoide (L.) P. Beauv. Doril muscular
relaxative Infusion (I, E) 3 1 1 0.17
5.4. Amaranthus aﬀ. viridis L. Caruru-de-
porco
wound healing,
pain, and kidneys Infusion (I) 4 3 3 0.50
5.5. Beta vulgaris L. Beterraba anemia Infusion (I) 1 1 1 0.17
5.6. Celosia argentea L. Crista-de-galo kidneys 5 3 3 0.50







Infusion (I, E) 102 7 8 1.23
5.8. Pfaﬃa glomerata (Spreng.) Pedersen Ginseng-
brasileiro Obesity Infusion (I) 2 1 1 0.17
6. ANACARDIACEAE





Infusion (I, E) 5 3 3 0.50








Infusion (I, E) 30 6 9 1.20











listed NCS NP RI





11 2 3 0.40














84 7 11 1.43
6.6. Spondias dulcis Parkinson Caja-manga scabies Infusion (I, E) 2 1 1 0.17
6.7. Spondias purpurea L. Seriguela wound healing
and hepatitis Infusion (I, E) 2 2 2 0.33
7. ANNONACEAE





decoction (I, E) 32 2 0 . 3 3
7.2. Annona crassiﬂora Mart. Graviola diabetes Infusion (I, E) 11 1 1 0.17
7.3. Duguetia furfuracea (A. St.- Hil.) Saﬀ. Beladona-do-
cerrado pain Infusion (I, E) 1 1 1 0.17
8. APIACEAE
8.1. Coriandrum sativum L. Coentro ﬂu Infusion (I) 1 1 1 0.17





Infusion (I) 3 2 2 0.33
8.3. Petroselinum crispum ((Mill) Fuss Salsinha ﬂu Infusion (I) 1 1 1 0.17




Infusion (I, E) 12 3 3 0.50
9. APOCYNACEAE
9.1. Aspidosperma polyneuron (M¨ ull.) Arg. P´ eroba Stomach and
laxative
Infusion and
decoction (I, E) 51 2 0 . 2 3
9.2. Aspidosperma tomentosum Mart. Guatambu gastritis Infusion (I) 4 1 1 0.17
9.3. Catharanthus roseus (L.) G. Don Boa-noite mumps fever and
kidneys Infusion (I) 8 3 3 0.50
9.4. Geissospermum laeve (Vell.) Miers Pau-tenente Diabetes and pain Infusion (I) 6 2 2 0.33







83 3 0 . 5 0




















listed NCS NP RI








Decoction (I) 5 6 8 1.13
9.8. Macrosiphonia velame (A. St.-Hil.) M¨ ull. Arg. Velame-branco ﬂu Decoction (I) 73 1 1 0.17
10. ARACEAE
10.1 Dieﬀenbachia picta Schott Comigo-
ningu´ em-pode pain Maceration (E) 2 1 1 0.17
10.2. Dracontium sp. Jararaquinha snakebite Infusion (I) 10 1 1 0.17
11. ARECACEAE





syrup (I) 20 4 4 0.67
11.2. Cocos nucifera L. Cocˆ o-da-bahia kidneys Maceration (I) 2 1 1 0.17
11.3. Orbignya phalerata Mart. Babac ¸u inﬂammation Decoction (I) 8 1 1 0.17
11.4. Syagrus oleracea (Mart.) Becc. Guariroba kidneys Maceration (I) 2 1 1 0.17
12. ARISTOLOCHIACEAE






Infusion (I) 11 4 5 0.73
12.2. Aristolochia esperanzae Kuntze Papo-de-peru wound healing Infusion (I) 3 1 1 0.17
13. ASTERACEAE
13.1. Acanthospermum australe (Loeﬂ.). Kuntze Carrapicho,
beijo-de-boi
colic, kidneys, and
runny cough Infusion (I) 31 2 3 0.40
13.2. Acanthospermum hispidum DC. Chifre-de-
garrotinho
Gonorrhea and
kidneys Infusion (I) 5 2 3 0.40





Infusion (I) 13 3 4 0.57






Infusion (I) 13 5 6 0.90







Infusion (I) 18 5 6 0.90
13.6. Artemisia vulgaris L. Artemisia insomnia Infusion (I) 3 1 1 0.17






Infusion (I) 39 4 5 0.73






Infusion (I) 31 5 7 0.97
13.9. Bidens pilosa L. Pic˜ ao-preto hepatitis, enteric,






listed NCS NP RI






Infusion (I) 13 2 3 0.40
13.11. Calendula oﬃcinalis L. Calˆ endula anxiety Infusion (I) 6 1 1 0.17




Infusion (I) 3 2 2 0.33




Infusion (I) 78 5 6 0.90
13.14. Chaptalia integerrima (Vell.) Burkart Lingua-de-vaca worms Infusion (I) 6 1 1 0.17





Infusion (I) 7 3 4 0.57





Infusion (I) 15 4 5 0.73




Infusion (I) 11 2 3 0.40
13.18. Emilia fosbergii Nicolson Serralha conjunctivitis Infusion (I) 6 1 1 0.17








11 3 4 0.57





Infusion (I, E) 10 3 3 0.50
13.21. Mikania glomerata Spreng. Guaco bronchitis cough Infusion (I) 14 2 2 0.33
13.22. Mikania hirsutissima DC. Cip´ o-cabeludo diabetes Infusion (I) 10 1 1 0.17
13.23. Pectis jangadensis S. Moore Erva-do-
carregador
blood cleanser
and diabetes Infusion (I) 4 2 2 0.33
13.24. Porophyllum ruderale (Jacq.) Cass. Pic˜ ao-branco Hepatitis and
kidneys Infusion (I) 11 2 2 0.33


















Infusion (I, E) 82 8 15 1.80
13.26. Spilanthes acmella (L.) Murray Jamb´ u liver Infusion (I) 5 1 1 0.17
13.27. Tagetes minuta L. Cravo-de-






listed NCS NP RI
13.28. Taraxacum oﬃcinale L. Dente-de-le˜ ao blood cleanser Infusion (I) 18 1 1 0.17





Infusion (I) 16 3 3 0.50
13.30.Vernonia condensata Baker Figatil-
caferana
cancer stomach
and liver Infusion (I) 48 2 3 0.40






syrup (I) 38 2 7 0.67
13.32. Zinnia elegans Jacq. Jacinta pain Infusion (I) 1 1 1 0.17
14. BERBERIDACEAE





bottle (I, E) 62 2 0 . 3 3
15. BIGNONIACEAE








bottle (I, E) 13 2 3 0.40




Infusion (I) 6 2 2 0.33





Infusion (I) 13 4 4 0.67
15.4. Jacaranda caroba (Vell.) A. DC. Caroba wound healing Decoction and
bottle (I, E) 31 1 0 . 1 7











bottle (I, E) 94 8 9 1.40
15.6. Tabebuia aurea (Silva Manso) B. & H. f. ex S. Moore Ipˆ e-amarelo worms Decoction and
bottle (I) 21 1 0 . 1 7








bottle (I, E) 67 6 10 1.27
15.8. Tabebuia impetiginosa (Mart. ex DC.) Standl. Ipˆ e-roxo prostate cancer
cough
Decoction and
bottle (I) 82 2 0 . 3 3
15.9. Tabebuia serratifolia Nicholson Pi´ uva prostate cancer Decoction and
bottle (I, E) 31 1 0 . 1 7
15.10. Zeyhera digitalis (Vell.) Hochn. Bolsa-de-
pastor Stomach Decoction and
bottle (I) 91 1 0 . 1 7
16. BIXACEAE











listed NCS NP RI










Infusion (I) 37 6 9 1.20
17. BOMBACACEAE





Infusion (I) 17 3 3 0.50
17.2. Eriotheca candolleana (K. Schum.) Catuaba prostate cancer 1 1 1 0.17
18. BORAGINACEAE
18.1. Cordia insignis Cham. Calc ¸˜ ao-de-
velho cough Infusion (I) 5 1 1 0.17





Infusion (I) 43 4 4 0.67




Infusion (I, E) 10 4 4 0.67
19. BRASSICACEAE
19.1. Nasturtium oﬃcinale R. Br. Agri˜ ao bronchitis Infusion (I) 2 1 1 0.17
20. BROMELIACEAE
20.1. Ananas comosus (L.) Merr. Abacaxi diuretic and
cough Infusion (I) 9 2 2 0.33
20.2. Bromelia balansae Mez Gravat´ a cough and
bronhitis Infusion (I) 2 2 2 0.33
21. BURSERACEAE
21.1. Commiphora myrrha (T. Nees) Engl. Mirra Menstruation and
rheumatism Infusion (I) 3 2 2 0.33







23 3 6 0.70
22. CACTACEAE
22.1. Cactus alatus Sw. Cacto Colic and guard
delivery Infusion (I, E) 10 2 2 0.33
22.2. Opuntia sp. Palma column 2 1 1 0.17
22.3. Pereskia aculeata Mill. Oro-pro-nobis anemia Infusion (I) 2 1 1 0.17
23. CAPPARACEAE
23.1. Crataeva tapia L. Cabac ¸a cough Infusion (I) 2 1 1 0.17
23.2. Cleome aﬃnis DC. Mussamb´ e diarrhea 1 1 1 0.17
24. CARICACEAE













listed NCS NP RI
25. CARYOCARACEAE





11 4 4 0.67
26. CELASTRACEAE







Infusion (I) 8 5 7 0.97
27. CECROPIACEAE









Infusion (I) 38 6 9 1.20
28. CLUSIACEAE
28.1. Kielmeyera aﬀ. grandiﬂora (Wawra) Saddi Pau-santo anemia 1 1 1 0.17
29. COMBRETACEAE
29.1. Terminalia argentea Mart. Pau-de-bicho itching, diabetes,
and cough 83 3 0 . 5 0
29.2. Terminalia catappa L. Sete-copa conjunctivitis Infusion (I, E) 2 1 1 0.17
30. COMMELINACEAE
30.1. Commelina benghalensis L. Capoeraba hemorrhoids Infusion (I) 1 1 1 0.17
30.2. Commelina nudiﬂora L. Erva-de-santa-
luzia
wound healing
and conjunctivitis Infusion (I) 3 2 2 0.33
30.3. Dichorisandra hexandra (Aubl.) Standl. Cana-de-
macaco
ﬂu, hypertension,
and kidneys Infusion (I) 1 3 3 0.50
31. CONVOLVULACEAE
31.1. Cuscuta racemosa Mart. Cip´ o-de-
chumbo pain Infusion (I) 1 1 1 0.17
31.2. Ipomoea batatas (L.) Lam. Batata-doce hearth Infusion (I) 1 1 1 0.17
31.3. Ipomoea (Desr.) Roem. & asarifolia Schult Batatinha-do-
brejo
Stomach and
worms Infusion (I) 4 2 2 0.33
32. COSTACEAE







Infusion (I) 40 3 5 0.63
33. CRASSULACEAE






juice (I) 11 2 4 0.47
34. CUCURBITACEAE
34.1. Cayaponia tayuya (Cell.) Cogn. Raiz-de-bugre blood cleanser,
pain, and hepatitis Infusion (I) 17 2 3 0.40
34.2. Citrullus vulgaris Schrad. Melˆ ancia bladder colic Infusion (I) 2 1 2 0.23






listed NCS NP RI
34.4. Cucumis sativus L. Pepino hypertension Maceration (I) 1
34.5. Cucurbita maxima Duchesne ex Lam. Ab´ obora Pain and worms Infusion (I) 4 2 2 0.33
34.6. Luﬀa sp Bucha Anemia and
kidneys Infusion (I) 7 2 2 0.33










Infusion (I) 50 6 10 1.27
34.8. Siolmatra brasiliensis (Cogn.) Baill. Taiu´ a Ulcer Infusion (I) 6 1 1 0.17
35. CYPERACEAE




Infusion (I) 12 3 4 0.57
35.2. Cyperus rotundus L. Tiririca Pain Infusion (I) 1 1 1 0.17
36. DILLENIACEAE





Infusion (I, E) 24 5 6 0.90
36.2. Davilla elliptica A. St.-Hil. Lixeira-de-cip´ o kidneys 3 1 1 0.17




Infusion (I) 10 3 4 0.57
37. DIOSCOREACEAE
37.1. Dioscorea sp. Car´ a-do-
cerrado boil Infusion (I) 25 1 1 0.17
37.2. Dioscorea triﬁda LC a r ´ a blood cleanser Infusion (I) 6 1 1 0.17
38. EBENACEAE
38.1. Diospyros hispida A. DC. Olho-de-boi Pain and leprosy Infusion (I) 5 2 2 0.33
39. EQUISETACAE
39.1. Equisetum arvense L. Cavalinha gastritis and
kidneys Infusion (I) 8 2 2 0.33
40. ERYTHROXYLACEAE
40.1 Erythroxylum aﬀ. Daphnites Mart. Vasoura-de-
bruxa syphilis Infusion (I) 1 1 1 0.17
41. EUPHORBIACEAE




Infusion (I) 6 2 2 0.33
41.2. Croton sp. Curraleira-
branca
uterine
inﬂammation Infusion (I) 3 1 1 0.17







Maceration (I) 37 5 9 1.10
41.4. Euphorbia aﬀ. Thymifolia L. Trinca-pedra kidneys Infusion (I) 3 1 1 0.17






listed NCS NP RI
41.6. Euphorbia tirucalli LA v e l o z cancer uterine
inﬂammation Maceration (I) 3 2 2 0.33
41.7. Jatropha sp. Capa-rosa diabetes Infusion (I) 10 1 1 0.17
41.8. Jatropha elliptica (Poh) Oken Purga-de-
lagarto allergy Infusion (I) 38 1 1 0.17








Maceration(I, E) 7 6 10 1.27
41.10. Jatropha urens L. Cansans˜ ao diabetes Maceration (I,
E) 61 1 0 . 1 7
41.11. Manihot esculenta Crantz Mandioca-
braba itching Maceration (I,
E) 21 1 0 . 1 7
41.12. Manihot utilissima Pohl. Mandioca itching Maceration (I,
E) 71 1 0 . 1 7





E) 82 2 0 . 3 3





E) 12 3 4 0.57
42. FABACEAE




Infusion (I) 19 2 4 0.47








Decoction (I) 16 5 7 0.97
42.3. Albizia niopoides (Spr. ex Benth.) Burkart. Angico-branco bronhitis Decoction (I) 1 1 1 0.17
42.4. Amburana cearensis (Allem˜ ao) A. C. Sm. Imburana cough Decoction (I) 13 1 1 0.17








Decoction (I) 12 5 6 0.90
42.6. Andira anthelminthica Benth. Angelim diabetes Decoction (I) 3 1 1 0.17
42.7. Bauhinia variegata L. Unha-de-boi kidneys Decoction (I) 4 1 1 0.17
42.8. Bauhinia ungulata L. Pata-de-vaca diabetes Infusion (I) 11 1 1 0.17





Infusion (I) 7 3 3 0.50
42.10. Bauhinia rubiginosa Bong. Tripa-de-
galinha kidneys Infusion (I) 2 1 1 0.17






listed NCS NP RI





Bottle (I) 20 4 6 0.80







E) 15 3 4 0.57
42.14. Cajanus bicolor DC. Feij˜ ao-andu diarrhea, stomach
and worms Infusion (I) 8 2 3 0.40





Infusion (I) 18 4 5 0.73





Infusion (I) 10 2 4 0.47
42.17. Copaifera sp. Pau-d’´ oleo wound healing,
kidneys, ulcer Infusion (I) 8 3 3 0.50







syrup (I) 13 5 6 0.90
42.19. Copaifera marginata Benth. Guaranazinho ulcer Infusion (I) 4 1 1 0.17





Infusion (I) 18 5 6 0.90








Infusion (I) 21 6 9 1.20
42.22. Dioclea latifolia Benth. Fruta-olho-de-
boi stroke Infusion (I) 3 1 1 0.17
42.23. Dioclea violacea Mart. Zucc. Coronha-de-
boi osteoporosis Infusion (I) 6 2 2 0.33
stroke








Infusion (I) 43 4 9 1.00




Infusion (I) 8 4 4 0.67











listed NCS NP RI







decoction (I) 31 5 6 0.90
42.28. Indigofera suﬀruticosa Mill. Anil ulcer Infusion (I) 2 1 1 0.17
42.29. Inga vera Willd. Ing´ a Laxative and
kidneys Infusion (I) 5 2 2 0.33
42.30. Machaerium hirtum (Vell.) Stellfeld Espinheira-
santa-nativa ulcer Infusion (I) 2 1 1 0.17
42.31. Melilotus oﬃcinalis (L) Pall. Trevo-cheiroso bone fractures
and thyroid Infusion (I) 5 2 2 0.33
42.32. Mimosa debilis var. vestita (Benth.) Barneby Dorme-dorme soothing Infusion (I) 2 1 1 0.17
42.33. Mucuna pruriens (L.) DC. Macuna stroke Infusion (I) 2 1 1 0.17
42.34. Peltophorum dubium (Spreng.) Taub. Cana-ﬁstula gastritis Infusion (I) 5 1 1 0.17
42.35. Platycyamus regnellii Benth. Pau-porrete anemia Infusion (I) 1 1 1 0.17







23 3 0 . 5 0
42.37. Senna alata (L.) Roxb. Mata-pasto throat, worms,
and vitiligo Infusion (I) 6 3 3 0.50




Infusion (I) 42 3 5 0.63
42.39. Stryphnodendron obovatum Benth. Barbatim˜ ao 1 wound healing Syrup and
decoction (I, E) 57 1 1 0.17










decoction (I, E) 15 4 9 1.00







juice (I) 30 6 7 1.07
43. FLACOURTIACEAE
43.1. Casearia silvestris Sw. Guac ¸atonga Epilepsy and
kidneys Infusion (I) 3 2 2 0.33
44. GINKGOACEAE
44.1. Ginkgo biloba L. Ginco-biloba vertebral Infusion (I) 1 1 1 0.17
45. HERRERIACEAE





Infusion (I) 12 3 4 0.57
46. HIPPOCRATEACEAE
46.1. Salacia aﬀ. elliptica (Mart. ex Schult.) G. Don Saputa-do-






listed NCS NP RI
47. IRIDACEAE





Infusion (I) 11 2 4 0.47
48. LAMIACEAE





Infusion (I) 23 5 5 0.83
48.2. Hyptis paludosa St.-Hil.ex Benht. Alevante cold Infusion (I) 4 1 1 0.17
48.3. Hyptis sp. Hortel˜ a-bravo Diabetes and
cough Infusion (I) 6 2 2 0.33





Infusion (I) 42 5 6 0.90











Infusion (I) 38 7 11 1.43
48.6. Marsypianthes chamaedrys (Vahl) Kuntze Alfavaca/Hort-
el˜ a-do-mato
ﬂu,hypertension,
and cough Infusion (I) 8 3 3 0.50
48.7. Melissa oﬃcinalis L Melissa soothing Infusion (I) 2 1 1 0.17
48.8. Mentha crispa L. Hortel˜ a-folha-
miuda
anemia, liver,
cough, and worms Infusion (I) 16 4 4 0.67




Infusion (I) 59 3 6 0.70





Infusion (I) 24 4 5 0.73
48.11. Mentha x piperita L. Hortel˜ a-
pimenta
bronchitis ﬂu,
cough and worms Infusion (I) 42 3 4 0.57
48.12. Mentha x villosa Huds. Hortel˜ a-
rasteira
stomach, ﬂu, cold,
and worms Infusion (I) 86 3 4 0.57
48.13. Ocimum kilimandscharicum Baker ex G¨ urke Alfavacaquinha ﬂu Infusion (I) 2 1 1 0.17
48.14. Ocimum minimum L. Manjeric˜ ao kidneys, sinusitis,
and worms Infusion (I) 7 3 3 0.50
48.15. Origanum majorana L. Manjerona heart Infusion (I) 4 1 1 0.17
48.16. Origanum vulgare L. Or´ egano cough Infusion (I) 1 1 1 0.17







syrup (I) 73 4 0 . 5 7
48.18. Plectranthus barbatus Andrews Boldo-
brasileiro
pain, stomach,
liver, and malaise Maceration (I) 99 2 4 0.47






listed NCS NP RI











maceration (I) 31 6 10 1.27
49. LAURACEAE
49.1. Cinnamomum camphora (L.) Nees & Eberm. Cˆ anfora pain Infusion and
maceration (I) 11 1 0 . 1 7
49.2. Cinnamomum zeylanicum Breyne Canela-da-
india
aphrodisiac, tonic,
obesity, and cough Infusion (I) 11 3 4 0.57





maceration (I) 31 3 3 0.50
50. LECYTHIDACEAE








maceration (I) 49 5 8 1.03
51. LOGANIACEAE
















107 8 14 1.73
52. LORANTHACEAE





maceration (I) 14 3 4 0.57
53. LYTHRACEAE
53.1. Adenaria ﬂoribunda Kunth Veludo-
vermelho kidneys 3 1 1 0.17









73 5 7 0.97
54. MALPIGHIACEAE
54.1. Byrsonima orbignyana A. Juss. Angiquinho wound healing Decoction and
maceration (I) 21 1 0 . 1 7
54.2. Byrsonima sp. Semaneira pain Infusion (I) 1 1 1 0.17
54.3. Byrsonima verbascifolia (L.) DC. Murici-do-






listed NCS NP RI
uterine
inﬂammation
54.4. Camarea ericoides A. St.-Hil. Arniquinha wound healing Infusion (I) 11 1 1 0.17





Infusion (I) 7 3 4 0.57









Decoction (I) 23 5 6 0.90
54.7. Malpighia emarginata DC. Cereja wound healing Infusion (I) 5 1 1 0.17




Infusion (I) 24 4 5 0.73
55. MALVACEAE
55.1. Brosimum gaudichaudii Tr´ ecul Mama-cadela stomach Infusion (I) 13 1 1 0.17






Infusion (I) 47 5 5 0.83





decoction (I) 10 4 4 0.67






Infusion (I) 2 3 4 0.57
55.5. Hibiscus rosa-sinensis L. Primavera pain Infusion (I) 2 1 1 0.17













Infusion (I) 18 10 13 1.87
55.7. Helicteres sacarolha A. St.-Hil. Semente-de-
macaco
Hypertension and
ulcer Infusion (I) 2 2 2 0.33








Infusion (I) 31 7 8 1.23





Infusion (I) 13 4 4 0.67
55.10. Sida rhombifolia L. Guaxuma obesity Infusion (I) 5 1 1 0.17
56. MELASTOMATACEAE






listed NCS NP RI
56.2. Tibouchina clavata (Pers.) Wurdack Cibalena pain Infusion (I) 3 1 1 0.17
56.3. Tibouchina urvilleana (DC.) Cogn. Buscopam-de-
casa stomach Infusion (I) 1 1 1 0.17
57. MELIACEAE
57.1. Azadirachta indica A. Juss. Neem diabetes Infusion and
decoction (I, E) 11 1 0 . 1 7
57.2. Cedrela odorata L. Cedro wound healing Infusion (I) 3 1 1 0.17
58. MENISPERMACEAE
58.1. Cissampelos sp. Orelha-de-
onc ¸a
Column and
kidneys Infusion (I) 3 2 2 0.33
59. MORACEAE
59.1. Artocarpus integrifolia L.f. Jaca diuretic Infusion (I) 1 1 1 0.17




Infusion (I) 2 2 2 0.33










Infusion (I) 41 7 12 0.50
59.4. Ficus brasiliensis Link. Figo gastritis Infusion (I) 4 1 1 0.17
59.5. Ficus pertusa L. f. Figueirinha stomach Infusion (I) 5 1 1 0.17
60. MUSACEAE





syrup (I) 93 3 0 . 5 0
61. MYRTACEAE






syrup (I) 22 3 6 0.70
61.2. Eugenia pitanga (O. Berg) Kiaersk. Pitanga pain, throat, ﬂu,
and kidneys Infusion (I) 10 3 4 0.57
61.3. Psidium guajava L. Goiabeira diarrhea Infusion (I) 19 1 1 0.17
61.4. Psidium guineense Sw. Goiaba-´ arac ¸a pain, diarrhea,
and hypertension Infusion (I) 11 3 3 0.50
61.5. Syzygium aromaticum (L.) Merr. & L. M. Perry Cravo-da-india Throat and cough Infusion (I) 5 1 2 0.23
61.6. Syzygium jambolanum (Lam.) DC. Azeitona-preta cholesterol Decoction (I, E) 4 1 1 0.17
62. NYCTAGINACEAE





Infusion (I) 22 2 4 0.47
62.2. Mirabilis jalapa L. Maravilha heart, pain, and
hypertension Infusion (I) 8 2 3 0.40
63. OLACACEAE
63.1. Ximenia americana L. Lim˜ ao-bravo Trush and diuretic Infusion (I) 4 2 2 0.33
64. OPILIACEAE
64.1. Agonandra brasiliensis Miers ex Benth. & Hook f. Pau-marﬁm uterine






listed NCS NP RI
65. ORCHIDACEAE
65.1. Vanilla palmarum (Salzm. ex Lindl.) Lindl. Baunilha hypertension Infusion (I) 2 1 1 0.17
65.2. Oncidium cebolleta (Jacq.) Sw. Orquidea pain Infusion (I) 2 1 1 0.17
66. OXALIDACEAE
66.1. Averrhoa carambola L. Carambola hypertension Infusion (I) 8 1 1 0.17
66.2. Oxalis aﬀ. hirsutissima Mart. ex Zucc. Azedinha obesity Infusion (I) 9 1 1 0.17
67. PAPAVERACEAE
67.1. Argemone mexicana L. Cardo-santo hypertension Infusion (I) 8 1 1 0.17
68. PASSIFLORACEAE
68.1. Passiﬂora alata Curtis Maracuj´ a Infusion (I) 9 1 1 0.17
68.2. Passiﬂora cincinnata Mast. Maracuj´ a-do-
mato
soothing
hypertension Infusion (I) 5 2 2 0.33
69. PEDALIACEAE





maceration (I) 12 2 5 0.53
70. PHYLLANTHACEAE
70.1. Phyllanthus niruri L. Quebra-pedra kidneys Infusion (I) 32 1 1 0.17
71. PHYTOLACCACEAE
71.1. Petiveria alliacea L. Guin´ e rheumatism Infusion (I, E) 4 1 1 0.17
72. PIPERACEAE




kidneys Infusion (I) 1 1 1 0.17
72.2. Piper cuyabanum C. DC. Jaborandi pain, stomach,
and loss of hair Infusion (I, E) 10 3 3 0.50




Infusion (I) 11 3 3 0.50
73. PLANTAGINACEAE
73.1. Plantago major L. Tanchagem heart, pain, and
laxative Infusion (I) 16 3 3 0.50
74. POACEAE
74.1. Andropogon bicornis L. Capim-rabo-
de-lobo
uterine
inﬂammation Infusion (I) 3 1 1 0.17
74.2. Coix lacryma-jobi L. L´ acrimas-de-
nossa-senhora kidneys Infusion (I, E) 4 1 1 0.17












juice (I) 49 5 12 1.30
74.4. Cymbopogon nardus (L.) Rendle. Capim-
citronela
ﬂu, cough, and
tuberculosis Infusion (E) 11 2 2 0.33












listed NCS NP RI





Infusion (I) 6 2 2 0.33




Infusion (I) 12 5 5 0.83







Infusion (I) 31 7 8 1.23
74.9. Oryza sativa L. Arroz bladder Infusion (I) 1 1 1 0.17
74.10. Saccharum oﬃcinarum L. Cana-de-
ac ¸ ´ ucar
kidneys, anemia,
and hypertension Infusion (I) 2 3 3 0.50
74.11. Zea mays L. Milho bladder kidneys Infusion (I) 3 2 2 0.33
75. POLYGALACEAE
75.1. Polygala paniculata L. Bengu´ e rheumatism Infusion (I) 6 1 1 0.17
76. POLYGONACEAE
76.1. Coccoloba cujabensis Wedd. Uveira diuretic Infusion (I) 1 1 1 0.17





Infusion (I) 41 5 6 0.90




Infusion (I) 6 4 4 0.67
76.4. Triplaris brasiliana Cham. Novatero diabetes Infusion (I) 1 1 1 0.17
77. POLYPODIACEAE
77.1. Phlebodium decumanum (Willd.) J. Sm. Rabo-de-
macaco
diuretic, hepatitis,
and kidneys Infusion (I) 9 2 3 0.40




Infusion (I) 8 3 3 0.50
77.3. Pteridium sp. Samambaia-
de-cipo rheumatism Infusion (I) 1 1 1 0.17
78. PONTEDERIACEAE
78.1. Eichhornia azurea (Sw.) Kunth Aguap´ e ulcer Infusion (I) 3 1 1 0.17
79. PORTULACACEAE
79.1. Portulaca oleracea L. Onze-horas hypertension Infusion (I) 3 1 1 0.17
80. PROTEACEAE
80.1. Roupala montana Aubl. Carne-de-vaca muscular
relaxative Infusion (I) 2 1 1 0.17
81. PUNICACEAE









41 3 6 0.70
82. RHAMNACEAE











listed NCS NP RI
83. ROSACEAE







63 3 0 . 5 0




11 1 0 . 1 7









tintura (I) 38 6 7 1.07
84. RUBIACEAE
84.1. Chiococca alba (L.) Hitchc. Cainca pain, ﬂu, and
rheumatism Infusion (I) 8 3 3 0.50
84.2. Cordiera edulis (Rich.) Kuntze Marmelada worms Maceration and
syrup (I) 31 1 0 . 1 7
84.3. Cordiera macrophylla (K. Schum.) Kuntze Marmelada-
espinho worms Maceration and
syrup (I) 11 1 0 . 1 7
84.4. Cordiera sessilis (Vell.) Kuntze Marmelada-
bola Flu and worms Maceration and
syrup (I) 42 2 0 . 3 3
84.5. Coutarea hexandra (Jacq.) K. Schum. Murtinha diarrhea Infusion (I) 1 1 1 0.17






syrup (I) 84 4 0 . 6 7
84.7. Guettarda viburnoides Cham. & Schltdl. Veludo-branco blood cleanser
and ulcer Infusion (I) 5 2 2 0.33










Infusion (I) 62 7 9 1.30
84.9. Palicourea rigida Kunth Dorad˜ ao Kidneys and
cough
Infusion and
decoction (I) 52 2 0 . 3 3






Infusion (I) 44 5 6 0.90
84.11. Tocoyena formosa (Cham. & Schltdl.) K. Schum. Jenipapo-bravo kidneys Infusion (I) 1 1 1 0.17




Infusion (I) 10 3 3 0.50
85. RUTACEAE
85.1. Citrus aurantiifolia (Christm.) Swingle Lima soothing hearth,
and hypertension Infusion (I) 8 2 3 0.40











listed NCS NP RI





Infusion (I) 30 4 6 0.80







Infusion (I) 57 4 8 0.93
85.5. Spiranthera odoratissima A.St.-Hil. Manac´ a rheumatism Infusion (I) 6 1 1 0.17






Decoction (I, E) 12 4 4 0.67
86. SALICACEAE
86.1. Casearia silvestris Sw. Ch´ a-de-frade blood cleanser,
pain, and fever Infusion (I) 10 1 3 0.30
87. SAPINDACEAE
87.1. Dilodendron bipinnatum Radlk. Mulher-pobre bone fractures Infusion (I) 5 2 2 0.33
uterine
inﬂammation
87.2. Magonia pubescens A. St.-Hil. Timb´ o wound healing,
pain, and cough
Maceration (I,
E) 72 3 0 . 4 0




Infusion (I) 9 2 3 0.40
87.4. Talisia esculenta (A. St.-Hil.) Radlk. Pitomba column, pain, and
rheumatism Infusion (I) 6 2 3 0.40
88. SAPOTACEAE
88.1. Pouteria glomerata (Miq.) Radlk. Laranjinha-do-
mato fever Infusion (I) 1 1 1 0.17
88.2. Pouteria ramiﬂora (Mart.) Radlk. Fruta-de-viado Ulcer and kidneys Infusion (I) 1 2 2 0.33
89. SCROPHULARIACEAE
89.1. Bacopa sp. Vicki-de-batata kidneys Infusion (I) 2 1 1 0.17











Infusion (I) 81 7 12 1.50
90. SIMAROUBACEAE






Maceration (I) 31 7 9 1.30










listed NCS NP RI
91. SIPARUNACEAE
91.1. Siparuna guianensis Aubl. Negramina pain, fever, and ﬂu Infusion (I) 20 2 3 0.40
92. SMILACACEAE
92.1. Smilax aﬀ. brasiliensis Spreng. Japecanga Column and
rheumatism Infusion (I) 5 1 2 0.23
93. SOLANACEAE
93.1. Capsicum sp. Pimenta Pain and
hemorrhoids Infusion (I, E) 14 2 2 0.33
93.2. Nicotiana tabacum L. Fumo thyroid Infusion (I, E) 2 1 1 0.17
93.3. Physalis sp. Tomate-de-
capote hepatitis Infusion (I) 1 1 1 0.17
93.4. Solanum americanum Mill. Maria-pretinha worms Infusion (I) 3 1 1 0.17
93.5. Solanum lycocarpum A. St.-Hil. Fruta-de-lobo Gastritis and ulcer Infusion and
maceration (I) 61 2 0 . 2 3
93.6. Solanum sp. Jurubeba column, stomach,
and liver Infusion (I) 8 2 3 0.40
93.7. Solanum sp. Urtiga boi Infusion (I) 1 1 1 0.17
93.8. Solanum melongena L. Berinjela cholesterol Infusion and
maceration (I) 21 1 0 . 1 7




13 2 2 0.33
93.10. Solanum viarum Dunal. Jo´ a-manso Hemorrhoids Infusion (I) 7 1 1 0.17
94. TILIACEAE
94.1. Apeiba tibourbou Aubl. Jangadeira liver Decoction (I, E) 1 1 1 0.17












syrup (I) 58 7 12 1.50
95. ULMACEAE
95.1. Trema micrantha (L.) Blume Piriquiteira wound healing Decoction (I, E) 1 1 1 0.17
96. VERBENACEAE






Infusion (I) 9 3 4 0.57
96.2.D u r a n t ar e p e n sL. Pingo-de-ouro diabetes Infusion (I, E) 3 1 1 0.17
96.3. Lantana camara L. Cambar´ a cold and cough Decoction (I) 22 2 2 0.33













listed NCS NP RI








Infusion (I) 19 4 7 0.87
96.6. Priva lappulacea (L.) Pers. Pega-pega Stomach and
sinusitis Infusion (I) 2 2 2 0.33









Infusion (I) 80 6 11 1.33
96.8. Stachytarpheta sp. Rabo-de-pav˜ ao relaxative
muscular Infusion (I) 3 1 1 0.17




Infusion (I) 8 3 4 0.57
97. VIOLACEAE





Infusion (I) 18 4 5 0.73
97.2. Hybanthus calceolaria (L.) Schulze-Menz. Poaia-branca cough Infusion (I) 1 1 1 0.17
98. VITACEAE
98.1. Cissus cissyoides L. Insulina-de-
ramo diabetes Infusion (I) 10 1 1 0.17
98.2. Cissus gongylodes Burch. ex Baker Cip´ o-de-arr´ aia relaxative
muscular Infusion (I) 1 1 1 0.17
98.3. Cissus sp. Rabo-de-arr´ aia hypertension Infusion (I) 3 2 2 0.33






Infusion (I) 5 3 3 0.50
99. VOCHYSIACEAE
99.1. Callisthene fasciculata Mart. Carv˜ ao-branco Hepatitis and
icterus Decoction (I, E) 10 2 2 0.33
99.2. Qualea grandiﬂora Mart. Pau-terra Diarrhea and pain Decoction (I, E) 5 2 2 0.33
99.3. Qualea parviﬂora Mart. Pau-terrinha diarrhea 1 1 1 0.17





Decoction (I, E) 4 4 4 0.67
99.5. Vochysia cinnamomea Pohl Quina-doce ﬂu 3 1 1 0.17













listed NCS NP RI
100. LILIACEAE











87 5 9 1.10
101. ZAMIACEAE
101.1. Zamia boliviana (Brongn.) A. DC. Maquin´ e stomach Infusion (I) 2 1 1 0.17
102. ZINGIBERACEAE




Infusion (I) 36 4 5 0.73





maceration (I) 18 4 5 0.73
102.3. Zingiber oﬃcinale Roscoe Gengibre pain, ﬂu, sinusitis,
and cough
Infusion and
maceration (I) 26 2 4 0.47
I: Internal, E: External; NSC: Number of body systems treated by species; NCS: number of body systems. NP: Number of properties of the species; RI: Relative
importance of the species.
Table 4: Species with the highest values of relative importance.
Family Species Application/citation RF RI
Apocynaceae Himatanthus obovatus (M¨ ull.
Arg.) Woodson
anemia (1), wound healing (7), cholesterol (3), blood cleanser
(9), pain (4), nose bleeding (1), hypertension (4), uterine
inﬂammation (5), labyrinthitis (6), muscle relaxant (2),
worms (1), vitiligo (1), and pneumonia (1)
45 1.87
Malvaceae Hibiscus sabdariﬀa L
anxiety/heart (1), ﬂu (1), tachycardia (1), kidneys (1), cramps
(3), discharge (1), diarrhea (1), pain (1), inﬂammation uterine
(2), labyrinthitis (3), snakebite (1), and pneumonia (2)
18 1.87
Asteraceae Solidago microglossa DC.
wound healing (53), blood cleanser (11), pain (2), bone
fractures (1), hypertension (1), uterine inﬂammation (3),
muscle relaxant (6), kidneys (3), and worms (2)
82 1.8
Loganiaceae Strychnos pseudoquina A. St.-Hil.
anemia (46), wound healing (3), cholesterol (1), blood
cleanser (16), pain (13), stomach (3), bone fractures (1), ﬂu
(2), uterine inﬂammation (1), pneumonia (1), muscle relaxant
(1), cough (10), ulcer (1), and worms (8)
107 1.73
Moraceae Dorstenia brasiliensis Lam.
wound healing (1), colic (1), tooth ache (1), blood cleanser
(4), dysentery (1), pain (7), ﬂu (2), laxative (3), menstruation
(1), pneumonia (6), relapse delivery (13), and kidneys (1)
41 1.5
Plantaginaceae Scoparia dulcis L.
heart (6), blood cleanser (1), diabetes (1), pain (16), bone
fractures (47), swelling in pregnant woman (4), pneumonia
(1), kidneys, ( 1) syphilis (3), and cough (1)
55 1.5
Malvaceae Luehea divaricata Mart.
uric acid (18), vertebral column (2), blood cleanser (1), throat
(1), ﬂu (1), hemorrhoids (7), intestine (1), pneumonia (8),
muscle relaxant (2), kidneys (3), cough (10), and tumors (4)
58 1.5
RF: Relative frequency; RI: Relative importance of the species.
traditional use as a blood cleansing, wound healing, and
other conditions associated with infections, which seems to
point to its possible antibiotic activity. Indeed, some studies
havedemonstratedtheinvitroactivityofitsdiﬀerentextracts
against promastigotes of Leishmania donovani [38]. A few
others also showed experimentally its antiviral, antitumor
activities, cellular proliferation activities, and inﬂammatory
a n di m m u n er e s p o n s e[ 39, 40]. On the basis of these
aforementioned,itispossiblethatitsuseinthefolkmedicine
may be related to its ability to modulate the immune system,
which may enhance physiological mechanisms involved
in resolving inﬂammation, pain, and wound healing.28 Evidence-Based Complementary and Alternative Medicine
Table 5: Categories of diseases, indications, form of use, preparation and the informant consensus factor of the main medicinal plants from
Nossa Senhora Aparecida do Chumbo District, Pocon´ e, Mato Grosso, Brazil.
Disease category/CID, 10th








of external causes— XIX
Scoparia dulcis L.
Solidago microglossa



















blood depurative Inf, Dec, and





(Cham.) K. Schum. Kidneys and diuretic Inf, Dec, and
Syr L (Fr, Dr) 132/533 0.75











ambrosioides L. verminose Inf, Mac, and
Juc L (Fr,Dr) 82/300 0.73
Diseases of the respiratory
system—X Mentha pulegium L. ﬂu, bronchitis, colds,
and cough
Dec, Inf,




Lam. childbirth Dec, Inf, and
Syr Rz (Fr, Dr) 9/28 0.70









Bidens pilosa L. Hepatitis and enteric Dec and Inf L (In, Sc) 3/7 0.67
Diseases of blood and






anemia Inf, Mac, and
Syr B (Fr, Dr) 15/38 0.62
Diseases of the eye and the
surrounding
structures—VII
Malva sylvestris L. Discharge and
conjuctivitis Inf and Tin L (Fr, Dr) 6/14 0.61
Diseases of endocrine of
nutritional and metabolic
origins—IV
Cissus cissyoides L. diabetes Inf L (Fr, Dr) 47/109 0.57
Diseases of the ear and
mastoid process—VIII
Himatanthus obovatus





DC. bone fractures Dec, Inf,
Mac, and Tin L (Fr, Dr) 70/146 0.52







Rz (Fr, Dr) 29/51 0.44




L (Fr, Dr) 22/38 0.43





leakage Inf 14/16 0.13
CID, 10th ed. categories of diseases in chapters according to International Classiﬁcation of Diseases and Related Health Problems, 10th. edition [25]; ICF:
informant consesus factor; Inf: infusion, Dec: decoction, Syr: syrup, Mac: maceration, Sal: salad, Tin: tinture, Juc: juice, Out: others (compression and bath).
L: leave; Wp: whole plant; Rt: root; Rz: rhizome; B: bark. State of the plant: Fr: fresh; Dr: dried.Evidence-Based Complementary and Alternative Medicine 29
We did not encounter any literature pertaining to its use
in anemia, nosebleeding, muscle relaxant, deworming, or
vitiligo treatment. Its indications as a blood cleansing and
as antihypercholesterolemic are important targets for future
biomedical research.
Hibiscus sabdariﬀa calyces are used in many parts of
the world to make cold and hot drinks as well as in folk
medicine [41]. Due to its many health-enhancing beneﬁts,
extensive works have been carried to validate its traditional
therapeuticclaims.Infact,itsmedicinalimportanceiswidely
acknowledged in many traditional herbal systems [42].
The beneﬁts associated with the use of H. sabdariﬀa
may in part be due to its high content of beneﬁcial phy-
tochemical constituents. These include alkaloids, L-ascorbic
acid, anisaldehyde, anthocyanin, β-carotene, β-sitosterol,
citric acid, cyanidin-3-rutinoside, delphinidin, galactose,
gossypetin, hibiscetin, mucopolysaccharide, pectin, proto-
catechuic acid, polysaccharide, quercetin, stearic acid, and
ﬂavonoids [42, 43]. Studies have highlighted the role of
polyphenol acids, ﬂavonoids, and anthocyanins that may
act as antioxidants or through other mechanisms that may
contribute to its cardioprotective activity [44, 45].
In additions to folkloric use of H. sabdariﬀa noted
in this study, other previous reports have indicated its
use in the treatment of liver disease, hypocholesterolemic,
antispasmodic, intestinal antiseptic, sedative, and as mild
laxative [42, 46]. The most extensively studied is its antihy-
pertensive activity. This eﬀect was conﬁrmed in several in
vitro and animal studies [47–49]. The hypotensive eﬀect of
H. sabdariﬀa and its constituents may be mediated, at least
partially, by a cholinergic and/or histaminergic mechanism
and it has been conﬁrmed to act via inhibitiory action on
angiotensin I converting enzyme, vasorelaxation [50], and
diuretic action [51]. For detailed review on this aspect, see
[41].Inadditiontoliteraturereportsonthemedicinalusesof
this plant, we also report here its indications in the treatment
of anxiety and labyrinthitis and as anti-snake venom. To
the best of our knowledge, these indications remained to be
proven experimentally.
In concordance with the traditional use of H. sabdariﬀa
in the treatment of uterine inﬂammation and pain, its aque-
ous ethanol extract was shown experimentally to presents
anti-inﬂammatory, uterine antispasmodic activities, and
attenuation of intestinal spasm [52–54]. In addition to its
conﬁrmed pharmacological activities, its antiobese/weight-
reducing [50, 55], hepatoprotective [56–58], anticancer
[46, 59, 60], free-radical scavenging [61], antioxidant [42],
immunomodulatory [62], lipid-lowering [43, 63]e ﬀects and
attenuation of oxidants-mediated complications in diabetes
[64] have been well documented. Besides, the plant extract is
characterized by a very low degree of toxicity [41]. Moreover,
apart from its medicinal uses, the plant seed oil was also
shown to be a good source of lipidsoluble antioxidants,
particularly γ-tocopherol, thus it could have important
industrial applications [65].
Solidago microglossa is popularly known in Brazil as
“arnica,” “arnica-do-mato,” “arnica-silvestre,” “erva-federal,”
“arnica-vulgar,” “erva-lanceta,” and “rabo-de-roj˜ ao” [66]. It
is usually confused with Arnica montana L., a native of the
mountainous regions of Europe, due to the similarity in
their medicinal ﬂowers and having the same color (yellow),
S. microglossa is not cultivated in Brazil due to it low
adaptation to the tropical conditions [66]. In our study,
S. microglossa was indicated for treatment of 15 diﬀerent
diseases corresponding to 8 classes of CID, 10th ed. and
had a total of 49 citations. The key citations for this plant
were its use in wound healing and blood cleansing. Other
popular indications found in this study were similar to those
previously reported, especially its use in the treatment of
wounds, acne, bruises, and stomach-related ailments [67].
Several classes of compounds and metabolites have
been isolated from S. microglossa, especially phenols, ace-
tophenones, carotenoids, lactones (helenalin and dihydro-
helenalin) [68, 69], ﬂavonoids [70, 71] saponins [72], and
polyacetylenes [70]. The cicatrizant activity of the plant’s
extract has been conﬁrmed experimentally [73]. Although
not mentioned directly by respondents in this study, some
lines of evidence suggest important antibiotic activity with
the use of S. microglossa, which can justify its indication
for uterine inﬂammation. Morel et al. [74] showed that the
essential oil of S. microglossa and three of its components
(quercetrin, α-espinasterol, and solidagenone) are capable
of signiﬁcantly inhibiting the growth of Staphylococcus
aureus, Staphylococcus epidermidis, Klebsiella pneumoniae,
Escherichia coli, Salmonella setubal, Bacillus subtilis, Pseu-
domonas aeruginosa, Saccharomyces cerevisiae, and Candida
albicans [74]. In addition, cicatrizant activity was observed
with the administration of the plant’s extract [73]. Its
use in ameliorating renal ailments, blood cleansing, and
hypotensive and antiparasitic activities may be associated
with the presence in high concentrations of tannins [75, 76]
and ﬂavonoids in this species [76–79]. Its indication for
muscle relaxation may also derive from its antispasmodic
eﬀect [80]. Further studies are warranted in these regards.
Other pharmacological properties not mentioned here,
but have been established in preclinical studies, include
hypoglycemic eﬀect [81] and antitumor activity. In fact, the
latter eﬀect has attracted intense interest in the discovery of
new chemotherapeutic agents. The extract of S. microglossa
demonstrated antiproliferative eﬀe c t( b u tn o tm u t a g e n i c )
against young shoot cells of onion (Allium cepa)s t r a i n[ 82].
Some of these activities may be related to the presence of
secondary metabolites such as helenalin [83].
Although Strychnos pseudoquina is referred to locally as
“quinas”, similar to the local name used for species such as
Cinchona sp. (source of quinine), it has been shown to be
inactive against Plasmodium berghei [84]c o n t r a ryt oi t sp o p -
ular use in folk medicine elsewhere [84]. Theoretically, some
of the indications may result from the classiﬁcation bias in
the community due to an erroneous popular cultural belief
that plants referred to as “quinas” are useful for “anemic”
patients infected with malaria parasite. This perhaps helps to
explain why the highest indication for this plant in our study
was to treat anemia.
Among the components isolated from S. pseudoquina
metabolites are isoramnetin, strychnobiﬂavone, and 11-
diaboline metoxidiaboline [85]. Silva et al. [86]d e m o n -
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of gastric lesions induced by nonsteroidal anti-inﬂammatory
agents and some necrotizing agents, thus conﬁrming its
indicationforgastriculcerandstomachdisordersasnotedin
thispresentstudy.Ontheotherhand,itsindicationinwound
healing has not been experimentally conﬁrmed at least in the
diabetic wound model in rats [87] or in local hemorrhage
induced by Bothrops jararaca venom [88]. Other medicinal
uses indicated like “blood depurative” and analgesic eﬀect
may be subject of future investigation as a potential agent
with antinociceptive and metabolic disorders ameliorating
eﬀects. Regarding its toxicity, Santos et al. [81] showed
that only the methanol extract (but not dichloromethane)
from the leaves of S. pseudoquina have mutagenic eﬀect
in Salmonella strains TA98 (−S9) and TA100 (+ S9, −S9)
and that it induces formation of micronuclei after acute
treatment [81].
Dorstenia brasiliensis, known as “Carapi´ a” is a peren-
nial herb of the early geological point of view, typical
of the ﬁelds in southern Brazil, Paraguay, Uruguay, and
Argentina [89, 90]. Phytochemical analysis of roots of D.
brasiliensis indicated the presence of dorstenic acid A and
B (triterpenoids), isopimarane-type diterpenoid, and six
diﬀerent types of coumarins. The two triterpenoids showed
moderate cytotoxicity against leukemia cells (L-1210 and
HL-60)[91].Furthermore,someauthorshavesuggestedthat
its use in cutaneow disease (such as psoriases and vitiligo)
may be associated with the presence of furanocoumarins
in the species of Dorstenia [92]. Bartericin A and
B, stigmasterol, isobavachalcone, 4-hydroxylonchocarpin,
dorsmanin F, 6,8-diprenyleridictyol, quercetin, quercitrin,
amentoﬂavone [93], psoralen, bergapten (from rhizome),
and umbelliferone [94] are some of the compounds isolated
this medicinal plant.
Some few pharmacological studies have demonstrated
analgesic and anti-inﬂammatory activities of D. brasiliensis
in animal models [95]. These data corroborated the popular
use of D. brasiliensis as an analgesic. There is dearth of
information conﬁrming its use in the popular medicine
use as an anti-inﬂammatory agent. Moreover, D. brasiliensis
may possesses some biologically active compounds similar to
other Dorstenia species from the same genus and may thus
share similar pharmacological proﬁle. The following com-
pounds and pharmacological activities have been reported
in other Dorstenia species: chalcones (D. prorepens and D.
zenkeri)[ 96], furocoumarins (D. bahiensis and D. bryoniifo-
lia), triterpenes (D. bahiensis, D. bryoniifolia, D. carauntae,
D. cayapiaa, and D. heringerii)[ 97]. This is a point to be
noted for future research. Some authors have investigated
its potential use as antivenom, antiinfective, anti-rheumatic
[96, 97] while others established its antitrichomonal [93],
antitussive [98], antioxidant [93, 99] and antileishmanial
[100] activities.
Scoparia dulcis, popularly known as “vassourinha”,
grows wild in backyards, gardens, and ﬁelds in Brazil.
Phytochemical studies have identiﬁed the presence of
more than 12 interesting pharmacologically active com-
pounds in this species, namely, scoparic acid A [101], iso-
dulcinol, 4-epi-scopadulcic acid B, dulcidiol, scopanolal,
dulcinol/scopadulciol, scopadiol [102], scoparinol [103],
scopadulcic acid B [104–106], glutinol [107] and scopadulin
[105]. Scopadulcic acid B inhibited the eﬀects of tumor pro-
moter 12-O-tetradecanoylphorbol-13-acetate (TPA) in vitro
and in vivo, and also suppressed the promoting eﬀect of TPA
onskintumorformation,demonstratingstrongereﬀectthan
antitumor-promoting terpenoids, such as glycyrrhetinic acid
[104]. In fact, its cytotoxicity has been investigated against
antitumor activity [102] and nerve growth factor-mediated
neurite outgrowth and neurodegenerative disorders [103,
108].
Theanalgesicandanti-inﬂammatoryactivitiesofethanol
extracts of S. dulcis and glutinol have been demonstrated
in writhing induced by acetic acid and carrageenan-induced
paw edema, respectively [107]. However, S. dulcis extracts
were ineﬀective in the central pain models (tail ﬂick)
and paw edema induced by dextran. Another secondary
metabolite, scoparinol, also showed signiﬁcant analgesic and
anti-inﬂammatory activity [109]. In regard to its toxico-
logical eﬀects, it is worthwhile to mention that glutinol
and scoparinol markedly potentiated pentobarbital-induced
sedation and duration of sleeping time in these two studies
mentioned above.
In contrast to its toxicity, S. dulcis seems to possess
potentialhepatoprotectiveactivityindiﬀerentmodels,which
have been attributed to its free-radical scavenging potential
activities [110–113]. Corroborating with antibiotic use for
some infections (like gonorrhea), some authors have inves-
tigated inhibition of multidrug resistance (MDR) bacteria,
fungi [114, 115], leishmanial parasite [116], and herpes
simplex virus type 1 growths [96].
Paradoxically, despite the low citation in gastric ulcer
and diabetes treatments in this study, the antiulcer and
antihyperglycemic activities of this species are well doc-
umented. Inhibitory activities of S. dulcis extracts was
demonstrated in pylorus ligature model, histamine- or
bethanechol-stimulated gastric secretion, and acute gastric
lesions induced by indomethacin [117, 118]. S. dulcis was
also demonstrated to inhibit both proton pump (H+,K +-
ATPase) and proton transport into gastric vesicles [105].
In regard to its antihyperglycemic eﬀect, experimental
evidences demonstrated that S. dulcis extracts reduced blood
glucose,glycosylatedhaemoglobin,preventeddecreaseinthe
body weight, and improved glucose tolerance similarly with
glibenclamide [119]. Even in the insulin resistance stage, S.
dulcis-treated L6 myotubes were found to be more capable of
stimulating glucose transport than insulin treatment [120].
In addition, scoparic acid D was able to stimulate insulin
secretion and receptor binding in streptozotoci- (STZ-)
induced diabetic rats [121].
Luehea divaricata is a native tree of the Brazilian Cerrado
popularly known as “ac ¸oita-cavalo”. Just as popularly indi-
cated, some studies have reported the following pharmaco-
logicalactivitiesofL.divaricata:theleavesasusedasdiuretic,
the stems as anti-inﬂammatory, the bark and aerial parts
are used for healing skin wounds, pimples, and for vaginal
washes [122, 123].
Phytochemical screening of L. divaricata reported the
presence of ﬂavonoids, tannins and saponins and aﬀorded
the presence of 3b-p-hydroxybenzoyl-tormentic acid [124],Evidence-Based Complementary and Alternative Medicine 31
maslinic acid [122], vitexin and glucopyranosylsitosterol,
and (−)-epicatechin [123].
The presence of ﬂavonoids and metabolites such as
the vitexin [125, 126] and maslinic acid [127, 128]m a y
be associated with the popular indication of its anti-
inﬂammatory properties formation of urate (18) and anti-
tumor (4). Extracts of L. divaricata has been shown to
have antioxidant activity and analgesic property [129], lack
toxicity in vivo [130], or mutagenicity [131]. Its extract also
showedcytotoxicityagainsttumorcelllines[123].Duetothe
high level of citation for the treatment of urate aleviation
(18), we believe that its antigout or uricosuric activity
may be an important target of pharmacological interest.
Another indication prominently cited by the respondents is
the use of L. divaricata in the treatment of lung diseases and
upper airway. However, there is no scientiﬁc evidence on its
regulatory activity on cough, while its antibiotic properties
also vary. Some authors have demonstrated its inhibitory
eﬀect on the growth of dermatophytes [132]b u tn o ti n
other fungi species [123, 129]. In addition, the extract of
L. divaricata was shown to strongly inhibit the growth of
S. aureus, S. epidermitis, K. pneumonia, and E. coli in a
study [129] but showed only moderately in another study
elsewhere [123].
It is worth mentioning that although Lafoensia pacari
A.St.-Hil.hadlowrelativeimportancevalue,allthesame,itis
among the three plants with the highest informant consesus
factor in addition to being a native plant in the region. The
other two (S. dulcis and S. microglossa) have been discussed
previously.
L. pacari popularly called “mangava-brava”, belongs to
the family Lythraceae, is a tree native to the Brazilian
Cerrado [133]. It is commonly used for gastrointestinal
disorders, wound healing, diarrhea, and kidney problems.
In our study, it was referenced for the treatment of seven
disorders distributed into ﬁve classes of CID, 10th ed.
Preliminaryphytochemicalstudiesofmethanolextractofthe
stem bark of L. pacari revealed the presence of free steroids,
saponins, tannins catechins, pyrogalic tannins (in particular,
ellagic acid), triterpenoids, simple phenols, strong and weak
ﬁxed acids, alkali, and quaternary amino acids [134–136].
Acute toxicity studies or subchronic oral administration of
extracts of L. pacari did not indicate any harmful eﬀects
[137]. However, it is also indicated for its adverse reactions
and used as an abortifacient, diarrheic, weight loss, and
tachycardia. Among the 42 citations for L. pacari,2 9w e r e
for the treatment of ulcer, and four and two for gastritis
and stomach, respectively. These indications have been
conﬁrmed with the use of methanol crude extract of L.
pacari and its major active components, ellagic acid, in
diﬀerent experimental ulcer models [138–143]. In addition,
the antiulcer activity of the methanol extract (capsules) of
L. pacari was conﬁrmed in the clinical trial with 55 patients
with dyspepsia [144].
Wedidnotencounteranystudiesconcerningitsactivities
in wound healing, antidiarrheal or alleviation of kidney
disorders. This phenomenon of plant selection by local
people for certain indications may be, for instance, to
consolidate best practice of the medicinal properties of the
plants at the expense of using other plants substitute for
these indications. In fact, the broad community access to
Amazon or Pantanal biome, and the close relationship with
the indigenous native populations, promotes a variety of
possibilitiesofethnobotanicalindications.Examplesofother
popular uses of L. pacari that have been experimentally
conﬁrmed includes weight loss [145], anorectic eﬀect [142],
antipyreticactivity[146],anti-inﬂammatory[147],antialler-
gic [148], and analgesic property [149].
It is also worth mentioning other studies focused on the
medicinal uses of L. pacari, including its potent antifungal
activity [150], have demonstrated that the main compound
responsible is found in the methanol extract of this plant. A
patent application of lotion with the infusion prepared from
the leaves of L. pacari, as a component of the formulation
was also solicited [151]. To the best of our knowledge, there
is currently no available literature concerning its claims as
wound healing, antidiarrheal, or in kidney disorders.
5. Conclusions
The present study identiﬁed the several plant species and
their medicinal uses in NSACD highlighting signiﬁcant
cultural diversity in the Pantanal region. In fact, one
of the important components of this community is the
contribution of Amerindian culture, which highlights its
importance in the identiﬁcation of indigenous popular
knowledge relevance in the identiﬁcation of native popular
knowledge.
Analytically, the data were categorized according to the
highest values of relative importance and consensus among
informants, ensuring the best evidence for ethnobotanical
bioprospectingofmedicinalplants.Thus,weidentiﬁedseven
nativespecieswiththehighestrelativeimportance,whichare
H. obovatus, H. sabdariﬀa, S. microglossa, S. pseudoquina and
D.brasiliensis, S. dulcis, and L. divaricata including L. pacari.
The three plants with the highest value of consensus among
informants were S. dulcis, S. microglossa, and L. pacari.
The preservation of local culture, the practice of tradi-
tional medicinal plant species themselves represent impor-
tant strategies for sustenance of popular knowledge of CAM
in the local systems of health care and environmental educa-
tion. Moreover, ethnobotanical and pharmacological studies
provide information essential for guidance in bioprospecting
for new drugs of plant origin in the consolidation of
therapeutic practices of the community.
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